REG - Hutchmed China Ltd - Blocklisting Six Monthly Return

HUTCHMED (China)Announcement

29/06/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230629:nRSc2357Ea&default-theme=true

RNS Number : 2357E  Hutchmed (China) Limited  29 June 2023

Blocklisting Six Monthly Return

 

Hong Kong, Shanghai, & Florham Park, NJ - Thursday, June 29, 2023:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the
"Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting
six monthly return:

 

 1.               Name of applicant:                                                              HUTCHMED (China) Limited

 2.               Name of scheme:                                                                 (a)                                       Share Option Scheme conditionally adopted by HUTCHMED in 2005 ("2005 HUTCHMED

                                                                                                                         Share Option Scheme")

                                                                                                  (b)                                       Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED
                                                                                                                                            Share Option Scheme")

 3.               Period of return:                                                               From December 29, 2022 to June 28, 2023

 4.               Balance under scheme from previous return:                                      (a)                                       2005 HUTCHMED Share Option Scheme: 883,300 ordinary shares of US$0.1 each

                                                                                                  (b)                                       2015 HUTCHMED Share Option Scheme: 52,667,578 ordinary shares of US$0.1 each

 5.               The amount by which the block scheme has been increased, if the scheme has      (a)                                       2005 HUTCHMED Share Option Scheme: Nil
                  been increased since the date of the last return:

                                                                                                  (b)                                       2015 HUTCHMED Share Option Scheme: Nil

 6.               Number of securities issued/allotted under scheme during period:                (a)                                       2005 HUTCHMED Share Option Scheme: 449,250

                                                                                                  (b)                                       2015 HUTCHMED Share Option Scheme: 936,860

 7.               Balance under scheme not yet issued/allotted at end of the period:              (a)                                       2005 HUTCHMED Share Option Scheme: 434,050 ordinary shares of US$0.1 each

                                                                                                  (b)                                       2015 HUTCHMED Share Option Scheme: 51,730,718 ordinary shares of US$0.1 each

 8.               Number and class of securities originally listed and the date of admission:     25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to

                                                                               replace the Company's previous block admission schemes following the Company's
                                                                                                  share subdivision which took effect on May 30, 2019)

 9.               Total number of securities in issue at the end of the period:                   866,161,450 ordinary shares of US$0.1 each

 Name of contact:                                                                                 Weiguo Su

 Address of contact:                                                                              Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong

                                                                                                Kong

 Telephone number of contact:                                                                     +852 2121 8200

 

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS

 Investor Enquiries
 Mark Lee, Senior Vice President                   +852 2121 8200
 Annie Cheng, Vice President                       +1 (973) 306 4490

 Media Enquiries
 Americas - Brad Miles,                            +1 (917) 570 7340 (Mobile) | bmiles@soleburystrat.com

                                                 (mailto:bmiles@soleburystrat.com)
 Solebury Strategic Communications
 Europe - Ben Atwell / Alex Shaw,                  +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

 FTI Consulting                                    +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                   (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi, Brunswick                         +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                   (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang,  +44 (20) 7886 2500

Panmure Gordon

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLREANKPAESDEEA